Milestone revenue volatility
Milestone revenue was lower at ₹44-45 crore vs normal run rate of ₹75 crore, impacting overall revenue growth.
medium · management_commentaryGland Pharma Limited — Q2 FY26
Gland Pharma reported a steady Q2 FY26 with consolidated revenue of ₹1,487 crore (+6% YoY) and EBITDA of ₹314 crore (21% margin).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Senexi turnaround execution
Senexi's planned shutdown and operational losses persist; breakeven in Q3 depends on achieving €50M quarterly revenue.
high · analyst_questionPrice erosion in US generics
While price erosion was flat this quarter, sustained competitive pricing could pressure margins in the base US business.
medium · data_observationGLP-1 capacity utilization ramp-up
New 100M cartridge capacity may take 2+ years to fully utilize, with revenue dependent on partner approvals and market access.
medium · analyst_question